Exchange: NASDAQ·Updated 04:10 PM EST

APRE News

News
all
press releases
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Lipocine Appoints Michael J. Grissinger to Board of Directors Lipocine Appoints Michael J. Grissinger to Board of Directors PR Newswire SALT LAKE CITY, Aug. 3, 2026 SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary...
PR Newswire
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.
Stocktwits
Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...
Benzinga
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
Zacks
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Zacks
Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...
MarketBeat

Advertisement|Remove ads.